低VS患者的生存率的比较. 介质前列腺特异性抗原度和名录的开发:监测,流行病学和最终结果计划数据库研究,在中国队列上进行外部验证
Jingchang Mei1, Guanqun Zhu1, Yu Yao1
1Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
PeerJ
|August 8, 2025
概括
低前列腺特异性抗原 (PSA) 水平表明前列腺癌晚期,高格里森评分 (GS 8-10) 的患者预后不佳. 相反,低PSA可能在早期疾病 (GS 6-7,T1) 中具有保护作用.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 生物统计学 生物统计学
背景情况:
- 前列腺癌是全球重要的健康问题.
- 前列腺特异性抗原 (PSA) 是一个关键的生物标志物,但它的解释可能很复杂.
- 了解低PSA水平的预后价值对于患者管理至关重要.
研究的目的:
- 研究低前列腺特异性抗原 (PSA) 度与前列腺癌进展和预后之间的关联.
- 为了确定低PSA的影响是否根据疾病阶段和格里森得分 (GS) 变化.
- 开发和验证前列腺癌生存率的预测模型.
主要方法:
- 对来自SEER计划的233,554名患者和来自青岛大学的199名患者进行了回顾性分析.
- 根据T阶段和格里森得分 (GS) 将分层划分为子组.
- 卡普兰 - 梅尔生存分析,多变量考克斯回归,以及生存预测的诺莫格拉姆开发.
主要成果:
- 低PSA度与高格里森评分 (GS8-10) 的患者的晚期疾病和不良预后有关.
- 低PSA度在具有较低格里森评分 (GS6-7) 和T1期疾病的患者中起到了保护因素的作用.
- 一个经过验证的诺莫格拉姆模型有效地预测了不同患者子组的预后.
结论:
- 低PSA度对前列腺癌有不同的预后影响,取决于T阶段和GS.
- 在高度前列腺癌 (GS8-10),低PSA是进展和糟糕的生存的重要危险因素.
- 一种新的诺莫图谱有助于预测前列腺癌患者的生存结果.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
377
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
194
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
287
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
287
01:21Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
01:24Kaplan-Meier Approach
266
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
266